Mogamulizumab
Poteligeo (mogamulizumab) is an antibody pharmaceutical. Mogamulizumab was first approved as Poteligeo on 2018-08-08. It is used to treat mycosis fungoides and sezary syndrome in the USA. It has been approved in Europe to treat mycosis fungoides and sezary syndrome. The pharmaceutical is active against C-C chemokine receptor type 4.
| Trade Name | Poteligeo |
|---|---|
| Common Name | Mogamulizumab |
| Indication | mycosis fungoides, sezary syndrome |
| Drug Class | Monoclonal antibodies: humanized, immunomodulating |
